loading
Schlusskurs vom Vortag:
$4.06
Offen:
$4.01
24-Stunden-Volumen:
72,584
Relative Volume:
0.60
Marktkapitalisierung:
$230.76M
Einnahmen:
$34.16M
Nettoeinkommen (Verlust:
$-98.43M
KGV:
-1.7692
EPS:
-2.34
Netto-Cashflow:
$-119.33M
1W Leistung:
-3.94%
1M Leistung:
-2.36%
6M Leistung:
-47.19%
1J Leistung:
-33.44%
1-Tages-Spanne:
Value
$3.98
$4.26
1-Wochen-Bereich:
Value
$3.88
$4.49
52-Wochen-Spanne:
Value
$2.9448
$10.25

Foghorn Therapeutics Inc Stock (FHTX) Company Profile

Name
Firmenname
Foghorn Therapeutics Inc
Name
Telefon
617-586-3100
Name
Adresse
500 TECHNOLOGY SQUARE, CAMBRIDGE
Name
Mitarbeiter
112
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-07
Name
Neueste SEC-Einreichungen
Name
FHTX's Discussions on Twitter

Vergleichen Sie FHTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
FHTX
Foghorn Therapeutics Inc
4.14 240.25M 34.16M -98.43M -119.33M -2.34
Biotechnology icon
ONC
Beigene Ltd Adr
238.76 24.41B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
434.03 111.55B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.2548 42.47M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
596.85 63.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
72.69 5.92B 0 -153.72M -103.81M -2.00

Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-23 Eingeleitet Citizens JMP Mkt Outperform
2025-01-30 Eingeleitet B. Riley Securities Buy
2024-09-03 Eingeleitet Jefferies Buy
2024-08-19 Eingeleitet Evercore ISI Outperform
2023-03-28 Eingeleitet BofA Securities Buy
2023-01-05 Eingeleitet BMO Capital Markets Outperform
2021-11-22 Eingeleitet H.C. Wainwright Buy
2020-11-17 Eingeleitet Cowen Outperform
2020-11-17 Eingeleitet Goldman Buy
2020-11-17 Eingeleitet Morgan Stanley Overweight
2020-11-17 Eingeleitet Wedbush Outperform
Alle ansehen

Foghorn Therapeutics Inc Aktie (FHTX) Neueste Nachrichten

pulisher
May 22, 2025

Foghorn Therapeutics Inc. to Participate in Major Upcoming Healthcare Conferences in 2025 - Nasdaq

May 22, 2025
pulisher
May 22, 2025

Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences - GlobeNewswire

May 22, 2025
pulisher
May 20, 2025

10,895 Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Acquired by Cubist Systematic Strategies LLC - Defense World

May 20, 2025
pulisher
May 19, 2025

(FHTX) Trading Report - news.stocktradersdaily.com

May 19, 2025
pulisher
May 19, 2025

Q2 EPS Estimate for Foghorn Therapeutics Cut by Analyst - Defense World

May 19, 2025
pulisher
May 19, 2025

Wedbush Expects Weaker Earnings for Foghorn Therapeutics - Defense World

May 19, 2025
pulisher
May 17, 2025

JMP Securities Reiterates Market Outperform Rating for Foghorn Therapeutics (NASDAQ:FHTX) - Defense World

May 17, 2025
pulisher
May 15, 2025

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates - MSN

May 15, 2025
pulisher
May 15, 2025

FHTX: JMP Securities Reiterates Market Outperform Rating for Fog - GuruFocus

May 15, 2025
pulisher
May 15, 2025

FHTX: JMP Securities Reiterates Market Outperform Rating for Foghorn Therapeutics | FHTX Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Foghorn Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 15, 2025
pulisher
May 14, 2025

Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Foghorn Therapeutics: Pioneering Precision Medicine with Innovative Pharmacology and AI Integration - TipRanks

May 14, 2025
pulisher
May 14, 2025

Foghorn Therapeutics Inc. reports results for the quarter ended March 31Earnings Summary - TradingView

May 14, 2025
pulisher
May 14, 2025

FHTX Exceeds Revenue Expectations and Advances Pipeline Programs - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Foghorn Therapeutics Advances FHD-909 Phase 1 Trial - TipRanks

May 14, 2025
pulisher
May 14, 2025

Foghorn Therapeutics Inc. SEC 10-Q Report - TradingView

May 14, 2025
pulisher
May 14, 2025

Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Foghorn Therapeutics Advances Cancer Drug Pipeline with Strong Financial Results: Phase 1 Trial Shows Promise - Stock Titan

May 14, 2025
pulisher
May 13, 2025

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Holdings Boosted by Wells Fargo & Company MN - Defense World

May 13, 2025
pulisher
May 13, 2025

Analysts Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) PT at $12.13 - Defense World

May 13, 2025
pulisher
May 12, 2025

Ted Myles Joins Cellarity as Chief Executive Officer - Stock Titan

May 12, 2025
pulisher
May 12, 2025

Barclays PLC Increases Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

May 12, 2025
pulisher
May 08, 2025

(FHTX) Trading Advice - news.stocktradersdaily.com

May 08, 2025
pulisher
May 07, 2025

Renaissance Technologies LLC Acquires 22,500 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

May 07, 2025
pulisher
May 06, 2025

Foghorn Therapeutics’ SWOT analysis: chromatin pioneer’s stock faces clinical hurdles - Investing.com Nigeria

May 06, 2025
pulisher
May 05, 2025

Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference - GlobeNewswire

May 05, 2025
pulisher
May 03, 2025

Foghorn Therapeutics (FHTX) Expected to Announce Quarterly Earnings on Monday - Defense World

May 03, 2025
pulisher
May 03, 2025

JPMorgan Chase & Co. Purchases 45,565 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

May 03, 2025
pulisher
May 02, 2025

Foghorn Therapeutics (NASDAQ:FHTX) Earns Buy Rating from HC Wainwright - Defense World

May 02, 2025
pulisher
May 01, 2025

Foghorn Therapeutics expands board with biotech veterans By Investing.com - Investing.com India

May 01, 2025
pulisher
May 01, 2025

Foghorn Therapeutics expands board with biotech veterans - Investing.com

May 01, 2025
pulisher
May 01, 2025

Foghorn Therapeutics Elects Neil Gallagher, M.D., Ph.D., and Stuart Duty to Board of Directors - Nasdaq

May 01, 2025
pulisher
May 01, 2025

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors - GlobeNewswire

May 01, 2025
pulisher
Apr 29, 2025

Foghorn Therapeutics Presents New Preclinical Data on Selective - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Geode Capital Management LLC Boosts Stake in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

Apr 29, 2025
pulisher
Apr 28, 2025

FHTX Unveils Promising Preclinical Data at Cancer Research Confe - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

Foghorn Therapeutics Presents Preclinical Data at AACR 2025 - TipRanks

Apr 28, 2025
pulisher
Apr 28, 2025

Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update | FHTX Stock News - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update - The Manila Times

Apr 28, 2025
pulisher
Apr 28, 2025

Foghorn Therapeutics Presents New Preclinical Data on - GlobeNewswire

Apr 28, 2025
pulisher
Apr 28, 2025

Breakthrough Cancer Drug FHD-909 Shows Synergy with Leading Treatments in Lung Cancer Studies - Stock Titan

Apr 28, 2025
pulisher
Apr 26, 2025

Foghorn Therapeutics (NASDAQ:FHTX) Research Coverage Started at JMP Securities - Defense World

Apr 26, 2025
pulisher
Apr 26, 2025

Foghorn Therapeutics (NASDAQ:FHTX) Earns Mkt Outperform Rating from Analysts at Citizens Jmp - Defense World

Apr 26, 2025
pulisher
Apr 23, 2025

This PayPal Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Apr 23, 2025
pulisher
Apr 23, 2025

JMP Securities Initiates Coverage of Foghorn Therapeutics (FHTX) with Market Outperform Recommendation - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Foghorn Therapeutics (FHTX) Gains Outperform Rating with $9 Targ - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

Foghorn Therapeutics (FHTX) Gains Outperform Rating with $9 Target | FHTX Stock News - GuruFocus

Apr 23, 2025
pulisher
Apr 18, 2025

Brokerages Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) Price Target at $13.17 - Defense World

Apr 18, 2025
pulisher
Apr 15, 2025

Foghorn Therapeutics to Host Virtual Investor Event to Review Pi - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting | FHTX Stock News - GuruFocus

Apr 15, 2025

Finanzdaten der Foghorn Therapeutics Inc-Aktie (FHTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$581.44
price down icon 0.60%
$1.39
price up icon 6.92%
$32.50
price down icon 0.28%
$289.00
price down icon 1.22%
$4.2299
price up icon 5.48%
$72.69
price down icon 1.89%
Kapitalisierung:     |  Volumen (24h):